Hormonal
Oral GLP-1 receptor agonists (orforglipron and oral semaglutide) produce clinically meaningful double-digit weight loss (11.2–13.6%) and cardiometabolic improvements in adults with obesity without diabetes, offering a viable alternative to injectable therapies.
Oral GLP-1 medications like orforglipron and oral semaglutide are now proven to help adults with obesity lose significant weight (11-13%) and improve heart health markers without needing injections. If you struggle with needles or prefer a pill, these are viable, effective options, though you should discuss specific dosing rules and potential side effects like nausea with your doctor.
These results confirm that oral GLP-1 receptor agonists can produce clinically meaningful weight loss and metabolic benefits, expanding options beyond injectables.
Why this rating
Based on large, multinational Phase 3 randomized controlled trials (ATTAIN-1 and OASIS-4).
Source
From needles to pills: oral GLP-1 therapy enters the obesity arena
Gaetano Santulli · Cardiovascular Diabetology – Endocrinology Reports · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →